The US Food and Drug Administration has said that it will limit the use of two monoclonal antibody therapies which do not seem to work well against the Omicron variant.

The combination antibody treatments bamlanivimab/etesevimab and casirivimab/imdevimab, made by Eli Lilly and Regeneron, respectively, worked well against earlier variants; however only a third antibody treatment, from GlaxoSmithKline, seems to work well against Omicron. Last week, the National Institutes of Health updated its guidelines advising against the use of the first two treatments among patients with mild to moderate COVID-19 on account of reduced effectiveness.

On the basis of latest data, the updated guidelines restrict the use of the Eli Lilly and Regeneron antibody treatments to only when the patient is likely to have contracted infection with or exposed to a variant which is susceptible to these treatments… (U.S. News, January 24, 2022)